Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 4/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025474 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL2024498 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL2025373 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL7988112 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL2022224 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL2023544 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL7992205 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL2025069 | 1.00 | SYK (0.43) | SYKCYP1A2CTSLCTSSCTSK | |
| SCHEMBL8000973 | 0.86 | KDM4E (0.42) | CTSLCTSSCTSKCTSBMEN1 | |
| SCHEMBL8076391 | 0.86 | KDM4E (0.42) | CTSLCTSSCTSKCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
| WO-2009154766-A1 | RENIN INHIBITORS AND METHOD OF USE THEREOF | VITAE PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | SYK 2988/4885CYP1A2 3186/4885CTSL 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.